Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(1.48) per share which beat the analyst consensus estimate of $(2.73) by 45.79 percent. This is a 82.59 percent increase over losses of $(8.50) per share from the same period last year.